Evidence map›Paper›PMID 32145791›Full record

ArticleLancet (London, England)2020

Challenging the management of drug-resistant tuberculosis - Authors' reply.

Christoph Lange, Keertan Dheda, Dumitru Chesov, Anna Maria Mandalakas, Zarir Udwadia, C Robert Horsburgh

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Lancet (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Christoph LangeClinical Infectious Diseases, Research Center Borstel, Borstel 23845, Germany; International Health and Infectious Diseases, University of Lübeck, Lübeck, Germany; German Center for Infection Research, Clinical Tuberculosis Unit, Borstel, Germany; Department of Medicine, Karolinska Institute, Stockholm, Sweden. Electronic address: clange@fz-borstel.de.
Keertan DhedaCentre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa; Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa; Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London School of Hygiene & Tropical Medicine, London, UK.
Dumitru ChesovClinical Infectious Diseases, Research Center Borstel, Borstel 23845, Germany; Department of Pneumology and Allergology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova.
Anna Maria MandalakasGlobal Tuberculosis Program, Texas Children's Hospital and the Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Zarir UdwadiaHinduja Hospital and Research Center, Veer Savarkar Marg, Mumbai, India.
C Robert HorsburghDepartment of Medicine, Boston University School of Medicine, Boston, MA, USA; Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA; Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA; Department of Global Health, Boston University School of Public Health, Boston, MA, USA.

Funding

Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment MonitoringR01AI137527 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI MANDALAKAS, ANNA M · 2019 to 2022
$2.7M
NIAID NIH HHS R01 AI137527
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Tuberculosis, Multidrug-ResistantAntitubercular AgentsHumansAntitubercular Agents

Identifiers

PMID32145791

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.